Passage Bio to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Passage Bio (NASDAQ: PASG), a clinical-stage genetic medicines company, has announced its participation in two upcoming investor conferences. The company will be present at the Canaccord Genuity 44th Annual Growth Conference on August 13, 2024, in Boston, MA, where management will give a presentation at 8:00 a.m. ET and participate in investor meetings. Additionally, Passage Bio will attend the 15th Annual Wedbush PacGrow Healthcare Conference on August 14, 2024, in New York City, NY, participating in investor meetings.

A live webcast of the Canaccord Genuity conference presentation will be available on the Investors & Media section of Passage Bio's website, with a replay accessible for 30 days following the event. This participation in investor conferences demonstrates Passage Bio's commitment to engaging with the investment community and sharing updates on their progress in developing treatments for neurodegenerative diseases.

PHILADELPHIA, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced that management will participate in the following upcoming investor conferences:

Canaccord Genuity 44^th Annual Growth Conference
Format: Management will participate in a presentation and investor meetings
Date: Tuesday, August 13, 2024
Presentation Time: 8:00 a.m. ET
Location: Boston, MA

15^th Annual Wedbush PacGrow Healthcare Conference
Format: Management will participate in investor meetings
Date: Wednesday, August 14, 2024
Location: New York City, NY

A live webcast of the presentation will be available on the Investors & Media section of Passage Bio’s website at investors.passagebio.com. A replay of the presentation will be available for 30 days following the event.

About Passage Bio

Passage Bio (Nasdaq: PASG) is a clinical stage genetic medicines company on a mission to improve the lives of patients with neurodegenerative diseases. Our primary focus is the development and advancement of cutting-edge, one-time therapies designed to target the underlying pathology of these conditions. Passage Bio’s lead product candidate, PBFT02, seeks to treat neurodegenerative conditions, including frontotemporal dementia, by elevating progranulin levels to restore lysosomal function and slow disease progression.

To learn more about Passage Bio and our steadfast commitment to protecting patients and families against loss in neurodegenerative conditions, please visit: www.passagebio.com.

For further information, please contact:

Investors:
Stuart Henderson
Passage Bio
267.866.0114
shenderson@passagebio.com

Passage Bio Media:
Mike Beyer
Sam Brown Inc. Healthcare Communications
312.961.2502
mikebeyer@sambrown.com

FAQ

When is Passage Bio (PASG) presenting at the Canaccord Genuity Growth Conference?

Passage Bio (PASG) is presenting at the Canaccord Genuity 44th Annual Growth Conference on Tuesday, August 13, 2024, at 8:00 a.m. ET in Boston, MA.

Which investor conferences is Passage Bio (PASG) attending in August 2024?

Passage Bio (PASG) is attending two investor conferences in August 2024: the Canaccord Genuity 44th Annual Growth Conference on August 13 in Boston, and the 15th Annual Wedbush PacGrow Healthcare Conference on August 14 in New York City.

How can investors access Passage Bio's (PASG) presentation at the Canaccord Genuity conference?

Investors can access a live webcast of Passage Bio's (PASG) presentation at the Canaccord Genuity conference on the Investors & Media section of the company's website at investors.passagebio.com. A replay will be available for 30 days after the event.

What type of company is Passage Bio (PASG)?

Passage Bio (PASG) is a clinical-stage genetic medicines company focused on developing treatments for patients with neurodegenerative diseases.